Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to wrap up the Steatotic Think-Thank on SLD, Mike Betel shares lessons from his 30-day Glucose Challenge, and Naim Alkhouri remembers Stephen Harrison while sharing his vision for the future of clinical trials and medical education.
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss other agents in development with unique modes of action and the ways that metabolic vs. pleiotropic effects will drive future drug choices.
This diverse episode includes a discussion of effective behavioral therapies, a look at drug development we did not discuss in prior episodes, and a sober discussion on how to do our best in addressing the important Washington Challenges under Trump and RFK Jr.
Hepatologist and Hepatology Key Opinion Leader Sven Francque joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss the current and future roles of NITs in Drug Development.
This week’s Newsmaker is Dutch Liver Patients Association President Jose Willemse. She discusses the patient screening program at the EASL Congress 2025 and the general idea of patient-sensitive dialogue with treaters.
Behavioral Scientist Dr. Kristina Curtis joins Jörn Schattenberg, Louise Campbell and Roger Green to discuss highlights of the Global Think Tank on SLD. This conversation focuses on the program’s history and different ideas on behavioral interventions.
This episode includes a discussion on patient management and self-management from the Global Think-Thank on Steatotic Liver Disease plus a segment from April’s Drug Development roundtable focusing on NITs in clinical trials. This week’s Newsmaker is Jose Willemse, President of the Dutch Liver Patients Association.
This week’s expert, hepatologist and Key Opinion Leader Scott Friedman, discusses the increasing acceptance of gene therapy in liver disease, evolving knowledge about the diversity of stellate cells and other advances in basic liver science. He closes with a request that all listeners do whatever we can to support NIH funding of science.
This week’s Newsmaker is hepatologist and key opinion leader Naga Chalasani of Indiana University. He discusses a recent article his group published in Hepatology Communications titled Early Experience with Resmetirom To Treat Metabolic-Associated Steatohepatitis with Fibrosis in a Real-World Setting.
The opening portion of SurfingMASH’s April roundtable on drug development looks at developments in the FGF-21 mode of action and, more generally, treatment of patients with cirrhosis, with tremendous enthusiasm.
